In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ...

However, the measurement of sIL-2R is simple compared to the complex story behind this biomarker that has become so central to the study of immune-mediated disease. Why measure soluble interleukin-2 ...

Interleukin-1 (IL-1) is a pro-inflammatory cytokine that mediates a diverse range of effects, in both the immune system and the central nervous system. The tight regulatory control of the actions of ...

Interleukin (IL)-1 is a prototypic proinflammatory cytokine. It is produced by numerous cell types (i.e., macrophages, synoviocytes, endothelial cells, chondrocytes, osteoclasts) and is found in ...

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of serious ...

Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...